More importantly, the separation of the survival curves among the patients receiving irinotecan pointed to a predictive utility of ABCG2 mRNA measurement in the adjuvant irinotecan treatment of patients with colon cancer. This evidence concerns the gene ABCG2 and colonic neoplasm.